Cargando…

The Synucleinopathies: Twenty Years On

In 2017, it is two hundred years since James Parkinson provided the first complete clinical description of the disease named after him, fifty years since the introduction of high-dose D,L-DOPA treatment and twenty years since α-synuclein aggregation came to the fore. In 1998, multiple system atrophy...

Descripción completa

Detalles Bibliográficos
Autores principales: Goedert, Michel, Jakes, Ross, Spillantini, Maria Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345650/
https://www.ncbi.nlm.nih.gov/pubmed/28282814
http://dx.doi.org/10.3233/JPD-179005
_version_ 1782513758046781440
author Goedert, Michel
Jakes, Ross
Spillantini, Maria Grazia
author_facet Goedert, Michel
Jakes, Ross
Spillantini, Maria Grazia
author_sort Goedert, Michel
collection PubMed
description In 2017, it is two hundred years since James Parkinson provided the first complete clinical description of the disease named after him, fifty years since the introduction of high-dose D,L-DOPA treatment and twenty years since α-synuclein aggregation came to the fore. In 1998, multiple system atrophy joined Parkinson’s disease and dementia with Lewy bodies as the third major synucleinopathy. Here we review our work, which led to the identification of α-synuclein in Lewy bodies, Lewy neurites and Papp-Lantos bodies, as well as what has happened since. Some of the experiments described were carried out in collaboration with ML Schmidt, VMY Lee and JQ Trojanowski.
format Online
Article
Text
id pubmed-5345650
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-53456502017-03-24 The Synucleinopathies: Twenty Years On Goedert, Michel Jakes, Ross Spillantini, Maria Grazia J Parkinsons Dis Review In 2017, it is two hundred years since James Parkinson provided the first complete clinical description of the disease named after him, fifty years since the introduction of high-dose D,L-DOPA treatment and twenty years since α-synuclein aggregation came to the fore. In 1998, multiple system atrophy joined Parkinson’s disease and dementia with Lewy bodies as the third major synucleinopathy. Here we review our work, which led to the identification of α-synuclein in Lewy bodies, Lewy neurites and Papp-Lantos bodies, as well as what has happened since. Some of the experiments described were carried out in collaboration with ML Schmidt, VMY Lee and JQ Trojanowski. IOS Press 2017-03-06 /pmc/articles/PMC5345650/ /pubmed/28282814 http://dx.doi.org/10.3233/JPD-179005 Text en IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Goedert, Michel
Jakes, Ross
Spillantini, Maria Grazia
The Synucleinopathies: Twenty Years On
title The Synucleinopathies: Twenty Years On
title_full The Synucleinopathies: Twenty Years On
title_fullStr The Synucleinopathies: Twenty Years On
title_full_unstemmed The Synucleinopathies: Twenty Years On
title_short The Synucleinopathies: Twenty Years On
title_sort synucleinopathies: twenty years on
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345650/
https://www.ncbi.nlm.nih.gov/pubmed/28282814
http://dx.doi.org/10.3233/JPD-179005
work_keys_str_mv AT goedertmichel thesynucleinopathiestwentyyearson
AT jakesross thesynucleinopathiestwentyyearson
AT spillantinimariagrazia thesynucleinopathiestwentyyearson
AT goedertmichel synucleinopathiestwentyyearson
AT jakesross synucleinopathiestwentyyearson
AT spillantinimariagrazia synucleinopathiestwentyyearson